Bringing the fundamentals into focus…
Back to Takeda Pharmaceutical Company Limited
How Takeda Pharmaceutical Company Limited stacks up
TAK · against 588 other Healthcare companies listed in US-listed
Valuation
44/ 100
Above the middle of the pack.
Ranked #210 of 589 · scores higher than 64% of peers
Bars: peers in each 10-point band of the valuation score45 peers with a valuation score of 40–49, including TAK · Click a bar to see the companies
Why valuation scores 44?
Weighted metrics compared with all Healthcare companies.A mix: stronger free cash flow yield and EBITDA yield, but weaker earnings yield than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -1.4% vs peer median 1.5%
- more operating profit (EBITDA) for the company's total value: stronger than 74% of peers. EBITDA yield: 4.9% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 77% of peers. Free cash flow yield: 8.1% vs peer median 0.0%
Metric by metric
Position: dot = TAK, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | TAK | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | Not reported | -4.3% | — | — | 30% |
| EBITDA yieldHigher is better · 578 reported | 8.0% | -0.8% | 83% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | 4.6% | -2.3% | 81% | 20% | |
| Book yieldHigher is better · 587 reported | 71.0% | 25.9% | 84% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around TAK| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 207 | 5.3B USD | 45 | 50 | |
| 210 | 10.5B USD | 44 | 56 | |
| 210 | 5.7B USD | 44 | 38 | |
| 210 | 1.3B USD | 44 | 58 | |
| 210 | 66.3B USD | 44 | 30 | |
| 210 | 5.9B USD | 44 | 39 | |
| 215 | 4.6B USD | 43 | 65 | |
| 215 | 1.7B USD | 43 | 35 | |
| 215 | 16.9B USD | 43 | 37 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score